OncoCyte (OCX) Stock Forecast, Price & News

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Is OncoCyte a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte or view top-rated stocks.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) announced its quarterly earnings data on Wednesday, May, 11th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. OncoCyte had a negative net margin of 877.80% and a negative trailing twelve-month return on equity of 52.12%.
View OncoCyte's earnings history.

What price target have analysts set for OCX?

5 brokerages have issued 1-year target prices for OncoCyte's stock. Their forecasts range from $1.40 to $6.00. On average, they anticipate OncoCyte's stock price to reach $3.90 in the next year. This suggests a possible upside of 252.9% from the stock's current price.
View analysts' price targets for OncoCyte or view top-rated stocks among Wall Street analysts.

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:

• Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 62, Pay $978.35k)
• Mr. Mitchell S. Levine, Chief Financial Officer
• Ms. Padma Sundar, Chief Commercial Officer
• Ms. Gisela A. Paulsen, Chief Operating Officer
• Ms. Li Yu, VP, Controller & Principal Accounting Officer
• Dr. Ekkehard Schutz M.D., Ph.D., Chief Technology Officer
• Mr. William Annett, Advisor (Age 68)
• Dr. Douglas T. Ross M.D., Ph.D., Chief Science Officer
• Mr. Robert S. Seitz, Head of Immune Oncology (Age 58)
• Dr. Michael D. West Ph.D., Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 69)

Who are some of OncoCyte's key competitors?

Some companies that are related to OncoCyte include Alpha Teknova (TKNO), VolitionRx (VNRX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), MyMD Pharmaceuticals (MYMD), Lucira Health (LHDX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Aspira Women's Health (AWH), Biomerica (BMRA), Quotient (QTNT), ARCA biopharma (ABIO), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB) and Navidea Biopharmaceuticals (NAVB).
View all of OCX's competitors.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), Brooklyn ImmunoTherapeutics (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.35%), Vanguard Group Inc. (4.32%), Defender Capital LLC. (2.78%), State Street Corp (1.47%), Northern Trust Corp (0.60%) and Goldman Sachs Group Inc. (0.50%). Company insiders that own OncoCyte stock include Albert P Parker, Alfred D Kingsley, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine and Ronald Asbury Andrews.
View institutional ownership trends for OncoCyte.

Which institutional investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., Nisa Investment Advisors LLC, Northern Trust Corp, State Street Corp, UBS Group AG, Renaissance Technologies LLC, and California State Teachers Retirement System.
View insider buying and selling activity for OncoCyte or view top insider-selling stocks.

Which institutional investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Defender Capital LLC., Vanguard Group Inc., Goldman Sachs Group Inc., Raymond James Financial Services Advisors Inc., DCF Advisers LLC, and Simplex Trading LLC. Company insiders that have bought OncoCyte stock in the last two years include Albert P Parker, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Mitchell S Levine, and Ronald Asbury Andrews.
View insider buying and selling activity for OncoCyte or or view top insider-buying stocks.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.11.

How much money does OncoCyte make?

OncoCyte has a market capitalization of $110.43 million and generates $7.73 million in revenue each year. The biotechnology company earns $-64.10 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does OncoCyte have?

OncoCyte employs 110 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (949) 409-7600, via email at [email protected], or via fax at 510-521-3389.